Gapping down
In reaction to disappointing earnings/guidance: WU -19.4%, CETV -18.2%, INVN -14.1%, IACI -13.6%, CYNI -12.2%, SODA -11.7%, SFLY -10.8%, YELP -8.9%, ( files mixed shelf offering; Specific terms of these offerings and securities will be provided in one or more supplements to this prospectus), QCOR -8.5%, PRXL -7.5%, RBCN -7.4%, HES -6%, (light volume), CALX -5.6%, (light volume), WBMD -5%, AUDC -4.8%, (light volume), XCO -4.4%, CAP -4.1%, (light volume), LNKD -3.7%, AFL -3%, (light volume), HTS -2.7% (light volume), MX -2.2%, CRUS -2.1%, GNW -1.9%, FLEX -1.7%, RYL -1.3%, DLR -1.3% (Digital Realty downgraded to Market Perform from Outperform at Raymond James, downgraded to Equal Weight from Overweight at Evercore), EXXI -0.9% (light volume), SO -0.5%.
Other news: MACK -17.2% (announces results from A Phase 2 Study Of MM-121 (SAR256212) in combination with Paclitaxel; MM-121 misses primary endpoint; ongoing biomarker analysis identifies a potential subpopulation of patients benefiting from MM-121 in combination with paclitaxel), AMRN -15.8% ( discloses FDA has rescinded the ANCHOR study special protocol assessment agreement, downgraded to Mkt Perform from Outperform at Leerink Swann ), PERI -14.8% (following IACI results), MTGE -5.9% (still checking), USU -3.2% (following late spike on DoE update), TEVA -2.7% (announces departure of President and CEO), MZOR -1.7% (price 2.4 mln ADSs at $17.00 per ADS), GRPN -1% (following YELP results), HCA -0.7% (announces 30 mln share sponsor secondary offering and concurrent company $500 mln share repurchase from sponsors).
Analyst comments: EW -4.1% (downgraded to Underweight from Neutral at JPMorgan ), CHKR -3.6% (downgraded to Sell from Neutral at Goldman), X -1.1% (downgraded to Hold from Buy at Deutsche Bank), UBS -0.4% (UBS downgraded to Neutral from Buy at BofA/Merrill)